The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

James D. Chalmers; Philipp Badorrek; Claudia Diefenbach; Harald Kögler; Wiebke Sauter; Stefan Kreideweiss; Jens M. Hohlfeld

doi:10.1183/23120541.00725-2023

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

James D. Chalmers (Lead / Corresponding author), Philipp Badorrek, Claudia Diefenbach, Harald Kögler, Wiebke Sauter, Stefan Kreideweiss, Jens M. Hohlfeld

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

75 Downloads (Pure)

Abstract

Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.

Original language	English
Article number	00725
Number of pages	5
Journal	ERJ Open Research
Volume	10
Issue number	2
Early online date	25 Jan 2024
DOIs	https://doi.org/10.1183/23120541.00725-2023
Publication status	Published - 1 Mar 2024

Access to Document

10.1183/23120541.00725-2023Licence: CC BY

Final published versionFinal published version, 343 KBLicence: CC BY

Cite this

@article{059ab8dc805c4f01b078b5201a4c32b6,

title = "The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583",

abstract = "Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.",

author = "Chalmers, {James D.} and Philipp Badorrek and Claudia Diefenbach and Harald K{\"o}gler and Wiebke Sauter and Stefan Kreideweiss and Hohlfeld, {Jens M.}",

note = "Copyright {\textcopyright}The authors 2024.",

year = "2024",

month = mar,

day = "1",

doi = "10.1183/23120541.00725-2023",

language = "English",

volume = "10",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "European Respiratory Society",

number = "2",

}

TY - JOUR

T1 - The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

AU - Chalmers, James D.

AU - Badorrek, Philipp

AU - Diefenbach, Claudia

AU - Kögler, Harald

AU - Sauter, Wiebke

AU - Kreideweiss, Stefan

AU - Hohlfeld, Jens M.

PY - 2024/3/1

Y1 - 2024/3/1

N2 - Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.

AB - Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.

U2 - 10.1183/23120541.00725-2023

DO - 10.1183/23120541.00725-2023

M3 - Letter

C2 - 38529344

SN - 2312-0541

VL - 10

JO - ERJ Open Research

JF - ERJ Open Research

IS - 2

M1 - 00725

ER -

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

Abstract

Access to Document

Fingerprint

Cite this